Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : SIFI
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : SIFI
Deal Size : Inapplicable
Deal Type : Inapplicable